• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cardiovascular therapeutics >Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia.
【24h】

Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia.

机译：中度和大剂量辛伐他汀对新发现的严重高胆固醇血症患者的不对称二甲基精氨酸-高半胱氨酸代谢途径的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The assumption that statin therapy can decrease asymmetric dimethylarginine through lowering low-density lipoprotein cholesterol levels seems logical and yet arises some controversy. The aim of the present study is to compare the effects of moderate (40 mg) to high (80 mg) simvastatin doses on asymmetric dimethylarginine and total homocysteine levels in patients with newly detected severe hypercholesterolemia (after target LDL-C levels, /=7.5 mmol/L and low-density lipoprotein cholesterol >/=4.9 mmol/L). Asymmetric dimethylarginine levels were determined by enzyme-linked immunosorbent assay, total homocysteine-by a high-performance liquid chromatographic method. There was a statistically significant decrease in total cholesterol, triglycerides, low-density lipoprotein cholesterol, and apolipoprotein-B levels as well as in the apolipoprotein-B/apolipoprotein-A1 index after a 1-month therapy with 40 mg simvastatin (P <0.001). Asymmetric dimethylarginine and total homocysteine levels were also decreased but the difference did not reach statistical significance (P= 0.571; P= 0.569). A dose-dependent effect was established, comparing the influence of moderate (40 mg) to high (80 mg) simvastatin doses on the tested atherogenic biomarkers (lipid profile, apolipoprotein-A1, and apolipoprotein-B). Asymmetric dimethylarginine and total homocysteine levels were lowered significantly with 80 mg simvastatin (P <0.001; P= 0.038). In conclusion, optimizing the target values of low-density lipoprotein cholesterol, a moderate dose (40 mg) of simvastatin has no effect on asymmetric dimethylarginine and total homocysteine in contrast to a high dose (80 mg) after target LDL-C levels are reached (
机译：他汀类药物疗法可通过降低低密度脂蛋白胆固醇水平来减少不对称二甲基精氨酸的假设似乎合乎逻辑，但引起了一些争议。本研究的目的是比较中等剂量（40 mg）至高剂量（80 mg）的辛伐他汀对新发现的严重高胆固醇血症患者的不对称二甲基精氨酸和总同型半胱氨酸水平的影响（在达到目标LDL-C水平后， / = 7.5 mmol / L和低密度脂蛋白胆固醇> / = 4.9 mmol / L）的成年患者。不对称二甲基精氨酸水平通过酶联免疫吸附测定，总高半胱氨酸含量通过高效液相色谱法测定。用40 mg辛伐他汀治疗1个月后，总胆固醇，甘油三酸酯，低密度脂蛋白胆固醇和载脂蛋白B水平以及载脂蛋白B /载脂蛋白A1指数均有统计学显着性下降（P <0.001 ）。不对称二甲基精氨酸和总同型半胱氨酸水平也降低，但差异未达到统计学显着性（P = 0.571; P = 0.569）。建立了剂量依赖性效应，比较了中等剂量（40 mg）和高剂量（80 mg）辛伐他汀对测试的致动脉粥样硬化生物标志物（脂质谱，载脂蛋白A1和载脂蛋白B）的影响。 80 mg辛伐他汀可显着降低不对称二甲基精氨酸和总同型半胱氨酸水平（P <0.001; P = 0.038）。总之，通过优化低密度脂蛋白胆固醇的目标值，适量的辛伐他汀（40 mg）对不对称二甲基精氨酸和总同型半胱氨酸没有影响，而达到目标LDL-C水平后的高剂量（80 mg）则相反（

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号